Increased dose of Empagliflozin may improve Glycemic control in T2 Diabetes patients
Researchers have found in a recent study that increasing the dose of Empagliflozin in Patients with Type 2 Diabetes significantly improved certain parameters like body weight, body mass index, γ-glutamyl transpeptidase, Triglycerides, fasting plasma glucose, and HbA1c while increasing hematocrit levels. The study was published in the journal, 'Diabetes Therapy, 2022.'
In T2 Diabetes sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors improve the blood glucose levels by inhibiting the reabsorption of glucose from the kidneys and thus increasing urinary glucose excretion. Though the SGLT2 inhibitors show a dose-dependent effect, there is not much research on the benefits of increasing the dose of SGLT2 inhibitors in clinical use. So, researchers from Japan conducted a study to explore the effect of an increased dose of the SGLT2 inhibitor empagliflozin in T2DM.
52 patients with T2DM with inadequate glycemic control participated in the study. The dose of empagliflozin was increased to 25 mg from 10 mg once a day and the alterations in the glycemic control and other parameters were analyzed.
Results:
Significant improvement in glycemic control was seen with an increased dose of empagliflozin.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.